Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, Erik Wallström, David K.B. Li et al.|The Lancet Neurology|2013Cited by 233
Bile Acids Metabolites as Predictors of long-term Multiple Sclerosis Progression (S5.004)Marianna Cortese, Alberto Ascherio, Kjetil Bjørnevik et al.|Neurology|2022Cited by 3
A Prospective Study of Serum Levels of Polyunsaturated Fatty Acids and Effects on Multiple Sclerosis Disease Activity and Progression (S40.006)Kassandra L. Munger, Alberto Ascherio, Xavier Montalbán et al.|Neurology|2022Cited by 3